Apollo agrees €3bn investment tied to Bayer contraceptives unit

Apollo has agreed to invest €3bn in Bayer through a minority, non-controlling position in a newly created vehicle that will hold Bayer’s long-acting reversible contraceptives business, PE Hub reported. The financing is intended to support the German pharmaceutical and life sciences group’s capital structure and give it more room to meet higher liquidity needs, according to the report.

The transaction places a defined Bayer business inside a newly established entity and brings in Apollo as a minority investor. In such a structure, the investor supplies capital against an ownership interest while the company retains control when the stake is non-controlling. PE Hub described Apollo’s position as both minority and non-controlling.

The asset referenced in the transaction is Bayer’s long-acting reversible contraceptives business. Long-acting reversible contraceptives are part of the broader healthcare and life sciences market, a field in which large pharmaceutical groups often hold portfolios of products with different growth, cash-flow and investment profiles.

Capital structure focus

PE Hub reported that the investment will help Bayer’s capital structure. For a corporate borrower or issuer, capital structure refers to the mix of financing sources used to fund operations and obligations, including equity-like capital and debt. Bringing in a minority investor at the level of a business-specific entity can raise funds without transferring operating control of the whole company.

The report also said the investment will provide Bayer with additional flexibility in handling increased liquidity requirements. Liquidity refers to available cash and funding capacity used to meet obligations, invest in operations or address near-term financial demands. The report did not attribute the liquidity requirements to a specific item.

Apollo, a global alternative asset manager, has used private capital structures across corporate transactions, including investments that sit between outright acquisitions and conventional lending. In this case, PE Hub identified the investment as a minority stake rather than a buyout of Bayer or the contraceptives business.

The deal adds to the flow of private capital into healthcare-related corporate assets, where established companies can raise financing from institutional investors while keeping operating control. Based on PE Hub’s account, the Bayer transaction is structured around a discrete business line rather than a group-wide equity issuance.

No additional transaction terms were included in PE Hub’s report beyond the €3bn investment amount, Apollo’s minority and non-controlling status, the creation of the new entity, and the Bayer business it will hold.

This story draws on original reporting from PE Hub.